MXPA05009336A - Compuestos de 2-propiliden-19-nor-vitamina d. - Google Patents

Compuestos de 2-propiliden-19-nor-vitamina d.

Info

Publication number
MXPA05009336A
MXPA05009336A MXPA05009336A MXPA05009336A MXPA05009336A MX PA05009336 A MXPA05009336 A MX PA05009336A MX PA05009336 A MXPA05009336 A MX PA05009336A MX PA05009336 A MXPA05009336 A MX PA05009336A MX PA05009336 A MXPA05009336 A MX PA05009336A
Authority
MX
Mexico
Prior art keywords
compounds
activity
diseases
treatment
bone
Prior art date
Application number
MXPA05009336A
Other languages
English (en)
Inventor
A Plum Lori
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33299883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05009336(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of MXPA05009336A publication Critical patent/MXPA05009336A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Se describen compuestos de 2-propiliden-19-nor-vitamina D, asi como usos farmaceuticos para estos compuestos y los metodos para sintetizar estos compuestos. Estos compuestos se caracterizan por alta actividad de movilizacion de calcio en huesos y alta actividad de transporte de calcio intestinal. Esto resulta en agentes terapeuticos novedosos para el tratamiento y profilaxis de enfermedades en donde se desea formacion de huesos, particularmente osteoporosis, asi como enfermedades autoinmunes tales como esclerosis multiple, diabetes mellitus y lupus. Estos compuestos tambien exhiben actividad pronunciada para frenar la proliferacion de celulas no diferenciadas e inducir su diferenciacion al monocito, evidenciando de esta manera el uso como un agente anti-cancer y para el tratamiento de enfermedades de la piel tales como psoriasis. Estos compuestos tambien incrementan tanto la resistencia a ruptura como al aplastamiento de huesos evidenciando el uso en conjunto con cirugia de reemplazo de huesos tales como reemplazos de cadera y rodilla.
MXPA05009336A 2003-04-10 2004-04-09 Compuestos de 2-propiliden-19-nor-vitamina d. MXPA05009336A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46195803P 2003-04-10 2003-04-10
PCT/US2004/011059 WO2004092118A2 (en) 2003-04-10 2004-04-09 2-propylidene-19-nor-vitamin d compounds

Publications (1)

Publication Number Publication Date
MXPA05009336A true MXPA05009336A (es) 2005-11-04

Family

ID=33299883

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009336A MXPA05009336A (es) 2003-04-10 2004-04-09 Compuestos de 2-propiliden-19-nor-vitamina d.

Country Status (15)

Country Link
US (3) US7241747B2 (es)
EP (1) EP1613588B1 (es)
JP (1) JP5005340B2 (es)
KR (1) KR20050120787A (es)
CN (2) CN100534981C (es)
AT (1) ATE556999T1 (es)
AU (1) AU2004230948A1 (es)
BR (1) BRPI0409194A (es)
CA (1) CA2516233C (es)
HK (1) HK1086817A1 (es)
MX (1) MXPA05009336A (es)
MY (1) MY146504A (es)
NZ (1) NZ542674A (es)
WO (1) WO2004092118A2 (es)
ZA (1) ZA200506204B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE556999T1 (de) * 2003-04-10 2012-05-15 Wisconsin Alumni Res Found 2-propyliden-19-nor-vitamin d verbindungen
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
MX2007009725A (es) * 2005-02-11 2007-09-26 Wisconsin Alumni Res Found 2-metilen-19-nor-(20s-24epi)-1a, 25-dihidroxivitamina-d2.
AU2006213727B2 (en) * 2005-02-11 2011-08-18 Wisconsin Alumni Research Foundation 2-methylene-19-nor- (20S-24S) - 1alpha, 25-dihydroxyvitamin-D2
US8114393B2 (en) 2005-09-14 2012-02-14 Wisconsin Alumni Research Foundation Methods and compositions for phosphate binding
US20090281340A1 (en) * 2006-04-05 2009-11-12 Deluca Hector F 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and treatment thereof
JP2009532482A (ja) 2006-04-05 2009-09-10 ウイスコンシン アラムニ リサーチ ファンデーション １α−ヒドロキシ−２−（３’−ヒドロキシプロピリデン）−１９−ノル−ビタミンＤ化合物類及びそれらの製造及び使用方法
EP2001841B1 (en) * 2006-04-06 2012-06-13 Wisconsin Alumni Research Foundation 2-methylene-1 alpha-hydroxy-18,19,21-trinorvitamin d3 analogs and uses thereof
WO2008035207A2 (en) * 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
AU2007298673A1 (en) 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2- substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof
WO2007118198A2 (en) * 2006-04-06 2007-10-18 Wisconsin Alumni Research Foundation 2-METHYLENE-1α,25-DIHYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF
US7538098B2 (en) * 2006-04-06 2009-05-26 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 1,2 or 3,2 heterocyclic ring
WO2008125901A2 (en) * 2006-04-06 2008-10-23 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof
US7763598B2 (en) 2006-04-10 2010-07-27 Wisconsin Alumni Research Foundation 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds with a 1,1-dimethylpropyl side chain

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0078704B1 (en) 1981-11-02 1987-04-29 Research Institute For Medicine And Chemistry Inc. Intermediates in the synthesis of vitamin d derivatives
US4666634A (en) 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
GB8904154D0 (en) 1989-02-23 1989-04-05 Leo Pharm Prod Ltd Chemical compounds
US5246925A (en) * 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
NZ232734A (en) 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
AU649057B2 (en) 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
DE69130497T2 (de) 1990-09-07 1999-04-22 Wisconsin Alumni Res Found Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
AU650751B2 (en) 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
JP3213092B2 (ja) * 1991-11-01 2001-09-25 中外製薬株式会社 ２β位に置換基を有するビタミンＤ誘導体
DE69400495T2 (de) * 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
US5565589A (en) * 1993-11-03 1996-10-15 Wisconsin Alumni Research Foundation 17-formyl-5,6-trans-vitamin D compounds
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
WO1996001811A1 (en) * 1994-07-11 1996-01-25 The Johns-Hopkins University 2-substituted 1,25-dihydroxyvitamin d3 derivatives
ATE176462T1 (de) * 1994-11-21 1999-02-15 Wisconsin Alumni Res Found 18,19-dinor-vitamin-d-derivate
US5877168A (en) * 1995-02-10 1999-03-02 Chugai Seiyaku Kabushiki Kaisha Vitamin D derivative with substituent at the 2β-position
CA2175881A1 (en) * 1995-05-09 1996-11-10 Andrzej Kutner Vitamin d compounds and methods of preparing these compounds
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
GB9915839D0 (en) * 1999-07-06 1999-09-08 Textron Automotive U K Valve assembly for vehicle washing system
EP1524264A3 (en) * 2000-05-31 2010-01-20 Wisconsin Alumni Research Foundation 2-ethylidene-19-nor-vitamin D compounds
JP4022141B2 (ja) * 2000-05-31 2007-12-12 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２−エチル及び２−エチリデン−１９−ノル−ビタミンｄ化合物
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
ATE556999T1 (de) * 2003-04-10 2012-05-15 Wisconsin Alumni Res Found 2-propyliden-19-nor-vitamin d verbindungen
EP1694333A2 (en) * 2003-11-25 2006-08-30 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds

Also Published As

Publication number Publication date
MY146504A (en) 2012-08-15
AU2004230948A1 (en) 2004-10-28
US20070213546A1 (en) 2007-09-13
JP2006523239A (ja) 2006-10-12
CA2516233A1 (en) 2004-10-28
US7241747B2 (en) 2007-07-10
KR20050120787A (ko) 2005-12-23
WO2004092118A2 (en) 2004-10-28
CN100534981C (zh) 2009-09-02
EP1613588A2 (en) 2006-01-11
JP5005340B2 (ja) 2012-08-22
HK1086817A1 (en) 2006-09-29
ZA200506204B (en) 2006-10-25
WO2004092118A3 (en) 2005-01-27
ATE556999T1 (de) 2012-05-15
US20040229851A1 (en) 2004-11-18
BRPI0409194A (pt) 2006-04-11
US20060293291A1 (en) 2006-12-28
NZ542674A (en) 2009-03-31
EP1613588B1 (en) 2012-05-09
CN101293894B (zh) 2011-04-06
US7531527B2 (en) 2009-05-12
CN1771226A (zh) 2006-05-10
CN101293894A (zh) 2008-10-29
CA2516233C (en) 2011-09-20

Similar Documents

Publication Publication Date Title
HK1086817A1 (en) 2- propylidene-19-nor-vitamin d compounds
MXPA03000405A (es) Uso de 2 alfa-metil-19-nor-20(s)-1alfa,25-dihdroxivitamina d3 para incrementar la resistencia de los huesos.
ATE534623T1 (de) 2-alkyliden-18,19-dinor-vitamin-d-verbindungen
MXPA03000406A (es) Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos.
EP1656157A4 (en) 2-METHYLENE-19-NOR-VITAMIN D2 COMPOUNDS
HK1080728A1 (en) (20s)-1alpha-hydroxy-2alpha-methyl, and 2beta-methyl-19-nor-vitamin d3 and their uses
NZ337262A (en) 2-alkyl-19-nor-vitamin D compounds and pharmaceutical compositions thereof
AU4790501A (en) 2-alkylidene-19-nor-vitamin d compounds and their therapeutic uses
CA2403232A1 (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
WO2006071773A3 (en) Treatment of osteochondral diseases using postpartum-derived cells and products thereof
Ferreira et al. Functional outcome of bicondylar tibial plateau fractures treated with the Ilizarov circular external fixator
Georgakis et al. Arterial supply to the sciatic nerve in the gluteal region
CN201350104Y (zh) 髌骨改良锁定钢板
MX9800801A (es) Proteina mp52 arg humana.
ATE350043T1 (de) 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen
Sayegh et al. Simultaneous bilateral fracture-dislocation of the talus: a case report
Iyer The Adult Hip and Its Disorders
CN211985568U (zh) 一种用于骨科的新型骨钻
Zhang et al. Bone Marrow Mesenchymal Stem Cells Exert Anti-Inflammatory and Chondrocyte Activity in Rats with Knee Arthritis
Huang et al. Bone Marrow Mesenchymal Stem Cells Inhibits Inflammation and Promotes Chondrocyte Activity in Knee Arthritis Rats
Chen et al. Growth Arrest Specific Gene 6 Affects Osteogenesis of Bone Marrow Mesenchymal Stem Cells in Inflammatory Environment via MAPK/AKT Signaling Pathway
DE60236411D1 (de) Verwendung von g-csf als zusätzliche behandlung in die wiederherstellung von bindegewebe
RU2011103666A (ru) Способ лечения тяжелых внутрисуставных переломов локтевого сустава в сочетании с переломами диафиза локтевой кости
CN101991917A (zh) 可调温骨外伤护架烤灯
AU2003274076A1 (en) Human chondroosteomodulin (tig2), production, and use for the treatment or diagnosis of bone diseases, cartilage diseases, obesity, inflammatory diseases, and skin diseases

Legal Events

Date Code Title Description
FG Grant or registration